论文部分内容阅读
目的肿瘤的转移是恶性肿瘤致死的主要原因之一,也是影响肿瘤治疗与预后的重要因素,E选择素(endothelial leukocyte adhesion molecule-1,ELAM-1)是导致肿瘤转移的关键步骤之一,以ELAM-1为靶点成为肿瘤靶向治疗的新研究热点。本研究总结国内外对ELAM-1靶向肿瘤转移的研究进展。方法应用ScienceDirect、PubMed及CNKI期刊全文数据库检索系统,分别以“肿瘤转移和靶向治疗、ELAM-1和肿瘤转移”等为关键词,检索2006-01-2016-12的国内外相关文献,共检索到英文文献6 092篇,中文文献7 063篇。纳入标准:(1)ELAM-1的生物学特点与生物学功能。(2)ELAM-1与常见肿瘤转移的关系。(3)ELAM-1靶向性调控与肿瘤转移情况。依据纳入排除标准,符合分析的文献27篇。结果 ELAM-1是细胞黏附分子家族的一员,其配体为唾液酸化的路易斯寡糖[sialyl-Lewis x,sLe(x)]或[sialylLewis a,sLe(a)]。通过ELAM-1单克隆抗体、ELAM-1分子偶联药物、ELAM-1配体sLe(x)表达抑制剂、ELAM-1/配体相互作用拮抗药物及ELAM-1表达抑制剂等可以抑制肿瘤转移、改善肿瘤预后。结论 ELAM-1与其配体的相互作用是介导肿瘤转移的关键,将ELAM-1及其调控路径作为治疗的靶点将有望成为肿瘤靶向治疗的突破口。
The purpose of the tumor metastasis is one of the main causes of death of malignant tumor, but also affect the tumor treatment and prognosis of an important factor, E-selectin (EL-1) is one of the key steps leading to tumor metastasis to ELAM-1 as a target to become a new hot topic of tumor targeted therapy. This study summarizes the research progress of ELAM-1 targeted tumor metastasis at home and abroad. Methods The full-text databases of ScienceDirect, PubMed and CNKI were searched, and the key words of “tumor metastasis and targeted therapy, ELAM-1 and tumor metastasis” were searched respectively. A total of 6 092 English articles and 7 063 Chinese articles were retrieved. Inclusion criteria: (1) The biological features and biological functions of ELAM-1. (2) the relationship between ELAM-1 and common tumor metastasis. (3) ELAM-1 targeting regulation and tumor metastasis. Based on the exclusion criteria included, 27 articles were analyzed. Results ELAM-1 is a member of the cell adhesion molecule family whose ligand is sialyl-Lewis x, sLe (x) or sialyl Lewis a, sLe (a). The tumor can be inhibited by ELAM-1 monoclonal antibody, ELAM-1 molecule conjugated drug, ELAM-1 ligand sLe (x) expression inhibitor, ELAM-1 / ligand interaction antagonist and ELAM-1 expression inhibitor Metastasis, improve tumor prognosis. Conclusion The interaction between ELAM-1 and its ligand is the key to mediate tumor metastasis. Taking the target of ELAM-1 and its regulatory pathway as a therapeutic target is expected to become a breakthrough in tumor targeted therapy.